Asymptomatic CMV Suppression with Letermovir Reduces Plasma Secondary Bile Acid Levels in Individuals with HIV on Long-term Antiretroviral Therapy: ACTG Study A5383 (EACS 2025) - Jul 16, 2025 - Abstract #eP180; Location: ePoster Exhibition; "These findings suggest that gut CMV may influence bacterial activity, microbiome composition, or barrier function, which could contribute to the immunologic changes observed with asymptomatic CMV suppression. Further studies should explore the impact of gut tissue CMV on the microbiome and bile acid transit."
Clinical • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • TNFA
|
|
J. Koethe 1; C. Wanjalla 1; D. Kitch 2; S. Qiu 2; D. Smith 3; M. Freeman 4; S. Gianella 3; P. Hunt 5; for the ACTG 5383 (ELICIT) Trial Team
|